Overall Survival With Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Study Update : Episode 2

Overview of CARTITUDE-4: Study Design, Baseline Characteristics, and Efficacy

October 18, 2024

By Binod Dhakal, MD, MS
Krina K. Patel, MD

Opinion

Video

Panelists discuss how the CARTITUDE-4 study data provide a comprehensive overview of its design, baseline characteristics, and efficacy outcomes, highlighting the potential of ciltacabtagene autoleucel in improving treatment results for patients with lenalidomide-refractory multiple myeloma.